Latest Breaking News On - Cullinan oncology - Page 10 : comparemela.com

Phase 3 Trials Reveal New Standards of Care for NSCLC

Data from several recent phase 3 trials support changes to standard care for NSCLC, according to researchers. Data from several recent phase 3 trials support changes to standard care for NSCLC, according to researchers.

Soult ukpyolsiSouth koreaUnited statesFrance generalRepublic of koreaEli lillyPerioperative pembrolizumabDaiichi sankyoBenjamin besseMedscape webInstitut curieRoche genentechByoung chul choZosia piotrowskaGustave roussyJarushka naidoo

C4 Therapeutics Inc (CCCC) Appoints Owen Hughes to its Board

C4 Therapeutics Inc (CCCC) Appoints Owen Hughes to its Board
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Rowen hughesBruce downeyRadius healthTherapeutics incDartmouth collegeFidelity investmentsCullinan oncologyIntarcia therapeuticsWall streetBrookside capitalBain capitalPyramis advisorsSail bioGurnet point capitalTranslate bio

Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Cullinan to provide clinical data updates on three novel targeted oncology programs and complete enrollment in the pivotal Phase 2b portion of the zipalertinib REZILIENT1 study in 2024

United kingdomCullinan pearlNadim ahmedRose weldonExchange commissionCullinan oncology incTaiho oncology incChief executive officerCullinan oncologyTaiho oncologyPrivate securities litigation reform actAnnual report

Form 8-K Cullinan Oncology, Inc For: Nov 08

Form 8-K Cullinan Oncology, Inc For: Nov 08
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomJeffrey trigilioCommission file numberSecurities exchangeCullinan oncology incSecurities exchange actIts charterPrincipal executive officesZip codeTelephone numberIncluding area codeFormer nameFormer addressChanged since last reportSecurities act

CLN-617 by Cullinan Oncology for Head And Neck Cancer Squamous Cell Carcinoma: Likelihood of Approval

CLN-617 is under clinical development by Cullinan Oncology and currently in Phase I for Head And Neck Cancer Squamous Cell Carcinoma.

United kingdomUnited statesGlobaldata pharmaceutical intelligence centerCullinan oncologyHead and neck cancer squamous cellPhase transition success rate modelPharmaceutical intelligence